Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
for End Stage Kidney Disease
147 locations incl. Decatur
Sponsor: CSL Behring
Sex: All·Age: 18+
Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022